Kevin M. Schaab

Statistics

Publications

Citations

155

H-Index

Active since

1996

Affiliations

Intercept Pharmaceuticals (United States)(Current)

PRA Health Sciences

Kevin M. Schaab is an author at Intercept Pharmaceuticals (United States) specializing in clinical pharmacology, 5-lipoxygenase inhibition, and pharmacology.

Publications per year

1996–2012

Publications

Lanthanide(III) complexation with ligands as possible contrast enhancing agents for MRI

Gregory R. Choppin, Kevin M. Schaab · Inorganica Chimica Acta · 1996 · 35 citations

Natural Sciences, Chemistry, Radiology +12

Suzuki Reaction of a Diarylborinic Acid: One-Pot Preparation and Cross-Coupling of Bis(3,5-dimethylphenyl)borinic Acid

Derick D. Winkle, Kevin M. Schaab · Organic Process Research & Development · 2001 · 31 citations

Natural Sciences, Chemistry, Organic Chemistry +7

Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5-Lipoxygenase-Activating Protein (FLAP)

Gretchen Bain, Christopher D. King, Melissa Rewolinski et al. · Clinical Pharmacology & Therapeutics · 2010 · 30 citations

Medicine, Pharmacokinetics, Pharmacology +13

An Approach to Early-Phase Salt Selection: Application to NBI-75043

Timothy D. Gross, Kevin M. Schaab, Michael A. Ouellette et al. · Organic Process Research & Development · 2007 · 28 citations

Pharmacy, Chemical Engineering, Inorganic Chemistry +11

Pharmacodynamics, pharmacokinetics and safety of <scp>GSK</scp>2190915, a novel oral anti‐inflammatory 5‐lipoxygenase‐activating protein inhibitor

Gretchen Bain, Christopher D. King, Kevin M. Schaab et al. · British Journal of Clinical Pharmacology · 2012 · 19 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

1–5 of 6